Abstract: Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable efficacy in NSCLC patients with EGFR mutation, and some relevant research has suggested that the presence of EGFR mutations is a favorable prognostic marker. However, the association of EGFR mutation status with the responsiveness to conventional chemotherapy agents and survival in NSCLC patients is still unclear. This review provides an overview of and assesses the role of EGFR as a prognostic marker for postoperative patients and as a predictive marker for response to cytotoxic chemotherapy. In addition, we review the comparison of response to chemotherapy between EGFR mutations in exon 19 and in exon 21 and the predictive role of p.T790M mutation.
Introduction
At present, lung cancer is the leading cause of carcinoma-related death in industrialized countries, 1 and 75%-80% of primary lung cancers are non-small-cell lung cancer (NSCLC). 2 Although surgical operation is the most effective therapy for NSCLC, many cases with advanced stage are unresectable, [3] [4] [5] and, for these patients, the preferred treatment is chemotherapy. Even though NSCLC patients have a chance to receive complete resection, they also face the risk of recurrence. 6 Therefore, whether certain biomarkers could exist as predictive factors of the chemotherapy and be used for decisions about treatment options is extremely important in clinical decision-making.
Epidermal growth factor receptor (EGFR) is a member of the ErbB receptor tyrosine kinase (TK) family and has an essential action in the development and progression of NSCLC. [7] [8] [9] It has been reported that the signaling pathways of EGFR could influence angiogenesis, activation and regulation of cellular proliferation, and the epithelial-mesenchymal transition ( Figure 1) . [10] [11] [12] [13] The gene with the most frequent mutations in NSCLC is EGFR. The most common EGFR mutations reported are deletions in exon 19 and the p.L858R point mutation in exon 21 (85%-90%). 14, 15 It has been reported that EGFR mutations usually occur in a subset of NSCLC patients with the following features: nonsmoker, female, East Asian, adenocarcinoma with bronchioloalveolar carcinoma, and well-or moderately differentiated tumor cells. [16] [17] [18] During the past decade, some research demonstrated that EGFR TK inhibitor (EGFR-TKI) sensitivity was influenced by the presence of EGFR mutations and increased EGFR copy numbers. [19] [20] [21] [22] [23] [24] [25] Some Phase III trials also revealed that, compared with those treated with erlotinib or gefitinib, the EGFR-mutated NSCLC
Trial identification criteria
Clinical randomized trials, prospective cohort studies, and retrospective studies were included. Studies that evaluated the relationship between EGFR mutations and the outcomes of NSCLC patients were included. In addition, the included studies had to satisfy the following criteria: patients had a pathological diagnosis of NSCLC; patients had a clear EGFR mutation status; and at least one outcome regarding response rate (RR) or survival time was reported.
Data extraction
Data recorded from each single study included authors' names, publication year, study design, objectives, sample 
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eGFR mutations in non-small-cell lung cancer size, EGFR mutation rate, and effects on patient outcomes (RR, survival, recurrence). Two reviewers independently conducted a data extraction from the original reports. Disagreements were resolved by consensus or by arbitration of a third reviewer.
Outcome definition
Based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines, 28 complete response and partial response (PR) were defined as the RR, and complete response, PR, and stable disease were defined as the disease control rate (DCR). Disease-free survival (DFS) was defined as the time from the date of surgery to proven recurrence or death. Progression-free survival (PFS) was defined as the time from the date of starting the therapy to disease progression or death. Overall survival (OS) was defined as the time from the date of surgery or starting the therapy to death or last follow-up. Post-recurrence survival was defined as the time from the date of recurrence to death or last follow-up. Time to treat ment failure (TTF) was defined as the time from the date of starting the treatment to disease progression or death. Two-sided P-values 0.05 were considered statistically significant.
EGFR mutations as a prognostic marker for postoperative patients with NSCLC
Recently, the predictive factors of postoperative prognosis in NSCLC patients have received much attention. Although outcomes after curative resection are improving, long-term survival time is still poor, resulting from a high rate of relapse. [29] [30] [31] Several studies have shown that the 5-year OS rates remained at 24%-58% after complete resection in stage IA-IIIA NSCLC patients. [32] [33] [34] Therefore, clarifying the role of EGFR mutation status in predicting the outcome of NSCLC patients with resection is essential clinical work.
The prognostic value of EGFR mutations in resected NSCLC remains debatable (Table 1) . Several studies have indicated that the presence of EGFR mutations meant longer survival times for patients with NSCLC who received surgical treatment. In a study by Lee et al 35 In a recent study performed by Jeon et al 36 138 patients who underwent surgical resection with adenocarcinoma and had postoperative recurrence were included in the research. EGFR mutation was an independent prognostic factor for post-recurrence survival (HR 0.552, P=0.013) and survival time (HR 0.552, 95% CI: 0.345-0.882, P=0.013) in multivariable analysis.
Similarly, Sasaki et al 37 analyzed the information of 95 NSCLC patients who underwent surgical resection. Compared with those with wild-type EGFR, they found that the patients with EGFR mutations had a longer survival time (P=0.0143). However, a multivariate analysis did not prove that EGFR mutation was the significant factor (P=0.1824). Kosaka et al 38 analyzed 397 Japanese patients who were treated with curative pulmonary resection with lung adenocarcinoma. Although the results of multivariate analysis showed EGFR mutations were not independent factors related to the prognosis (P=0.3225), the authors found that the EGFR mutation patients had a longer survival time than those with wild-type EGFR.
A study by D'Angelo et al 39 enrolled the largest cohort ever reported (n=1,118) in an investigation of whether EGFR mutations could be used to predict the prognosis of postoperative patients with NSCLC EGFR mutation was detected in 222 (19.9%) patients. The results showed that patients with EGFR mutations had a lower risk of death (HR 0.51, P0.001) and a longer OS (HR 0.51, 95% CI: 0.34-0.76, P0.001) than those with EGFR wild-type. They also found that a survival time of more than 10 years (n=286) only occurred in patients with EGFR mutation in lung cancer.
However, several studies revealed that EGFR mutation status had no prognostic value in patients who underwent surgical resection with adenocarcinomas. A total of 131 patients with completely resected lung adenocarcinoma whose pathologic stage was IA-IIIA were included in a study by Liu et al 40 in which no significant correlation was observed between median DFS (36.6 versus 25.7 months, P=0.533), OS (P=0.564), the recurrence rate, and EGFR mutation status. The results of multivariate analysis revealed that the lymph node (N) status (P=0.037) and distant metastasis (P0.001) were significant predictive factors for OS.
Kobayashi et al 41 
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eGFR mutations in non-small-cell lung cancer the curative effect of chemotherapy for NSCLC has reached a plateau. 49, 50 There is an urgent need to develop individualized treatments for NSCLC patients. Some research has indicated that EGFR mutations may be used as a predictive marker for the response to conventional cytotoxic chemotherapies (Table 2) . [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] Although the results of these studies differed, they may suggest that there is a certain correlation between EGFR mutations and the response to cytotoxic agents.
The IRESSA Pan-Asia Study (IPASS) 51, 52 was a randomized Phase III study that included 1,217 patients with advanced lung adenocarcinoma from 87 clinical research centers of nine Asian countries. The purpose of the study was to compare the efficiency of gefitinib and carboplatin/paclitaxel. The researchers found that the RR was higher in EGFR mutation patients compared with wild-type EGFR cases (47.3% versus 23.5%). The research revealed that EGFR mutations may be a favorable predictive factor for the response to cytotoxic chemotherapy in NSCLC patients. However, the results of another Phase III trial indicated that patients with EGFR mutations had a similar RR to EGFR wild-type patients after receiving chemotherapy. 53 In the first-line randomized Phase III Iressa NSCLC Trial Assessing Combination Treatment (INTACT) trials, Bell et al 54 found that EGFR mutationpositive patients treated only with chemotherapy had a better OS (19.4 versus 9.2 months) than those with wild-type mutations, but there was no significant difference in RR between the two groups (40.0% versus 39.0%).
Similar results were found in other studies. The study by Eberhard et al 55 indicated that the presence of EGFR mutations was associated with higher RR (38% versus 23%, P=0.01) and longer time to progression despite a therapeutic regimen (8.0 versus 5.0 months, P0.001). The study by Hotta et al 56 demonstrated that EGFR mutations were significantly correlated with a better PFS (HR 0.422, P=0.0422) and OS (HR 0.263, P=0.0074) in 54 Japanese patients with advanced NSCLC receiving first-line cytotoxic regimens, whereas they observed that the objective response was not affected by the presence of EGFR mutations (P=0.6842). However, the correlation of EGFR mutation with PFS was not found in the patients who received chemotherapy after the failure of the first-line gefitinib (P=0.0764).
Kalikaki et al 57 evaluated the clinical outcome of 162 patients with advanced NSCLC who received first-line chemotherapy and divided patients with EGFR mutations into two groups, which included those who had classical activating mutations (Del19, p.L858R, p.G719D, and p.E746V) and those who carried other mutations of unknown effect. The data indicated that patients with were included in the study. A total of 27 patients with resected lung adenocarcinomas were enrolled in a study performed by Lim et al. 43 EGFR mutations were detected in 15 patients (55.6%). The results showed there was no significant difference in DFS (16.87 versus 18.13 months, P=0.83) and OS (P=0.45) between EGFR mutation patients and those with wild-type EGFR. Similarly, among 393 Japanese patients who underwent a complete resection of adenocarcinoma in a study by Nose et al 44 there was no significant DFS difference between EGFR mutation patients and patients with wild-type EGFR (P=0.367).
At present, EGFR and KRAS mutations are known for having biologic relevance. Marks et al 45 analyzed the clinical outcomes data of 296 patients with stage I-III lung adenocarcinoma who underwent resection and compared outcomes between patients with EGFR mutation and KRAS mutation. The results revealed that patients with EGFR mutation had a higher 3-year OS than patients with KRAS mutant tumors (90% versus 66%) and suggested the NSCLC patients with EGFR mutation might have a more favorable prognosis.
Based on the previous studies, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] the prognostic role of EGFR mutations was not clear in patients with resected NSCLC. Although several studies did not report a significant difference in survival time between patients with and without EGFR mutations who underwent a resection of NSCLC, [40] [41] [42] [43] [44] we believe that the presence of EGFR mutations is related to improved prognosis because of the better clinicopathologic characteristics. However, we cannot obtain a certain conclusion on this issue because of different postoperative treatments and the small population of patients in previous research. Therefore, further prospective studies are needed to investigate the prognostic value of EGFR mutations after surgical resection.
EGFR mutations as a predictive marker for response to cytotoxic chemotherapy in NSCLC First-line treatment
Platinum-based doublet chemotherapy is the standard firstline therapy for advanced-stage NSCLC. [46] [47] [48] 3 suggested that EGFR mutations had a relationship with survival time rather than with the response to first-line chemotherapy in patients with advanced NSCLC.
There are some related studies which indicate that certain therapies could demonstrate higher efficiency in NSCLC patients with EGFR mutation. Dong et al 58 reviewed 229 patients with advanced NSCLC who received platinumbased doublet chemotherapy as the first-line treatment. Although the RRs were not influenced by EGFR mutation status, there was significant difference in the PFS between patients with wild-type EGFR and EGFR mutations (8.3 versus 9.1 months, P=0.008). In 120 patients with EGFR mutation, DCR was higher in patients treated with docetaxel when compared with patients treated with gemcitabine (88.6% versus 67.5%, P=0.031), and docetaxel-or vinorelbine-based treatment showed a longer PFS compared to gemcitabine (9.4, 9.6, and 8.3 months, respectively, P=0.033 and P=0.028). Multivariate analysis indicated that the presence of an EGFR mutation was an independent predictive factor for PFS to first-line chemotherapy (95% CI: 1.086-1.840, P=0.01).
Park et al 59 included 217 patients with advanced NSCLC who had received platinum doublet chemotherapy as a In the BR.21 trial, 63, 69 researchers compared erlotinib with a placebo in advanced NSCLC patients. Among the placebo subgroup, the data showed that patients with classical mutations had a longer median survival time than patients with EGFR wild-type or novel EGFR mutations (9.1, 3.5, and 3.5 months, respectively). However, there was no significant survival difference between EGFR classical or novel mutation patients and patients with wild-type EGFR (HR 0.65, 0.67, and 0.73, respectively).
As we can see from the results of the abovementioned studies, it has not been established whether EGFR mutations could predict the outcomes in NSCLC patients treated with cytotoxic chemotherapy. Regarding the results that showed that NSCLC patients with EGFR mutations achieved better therapeutic effect and longer survival time, one possible reason is that EGFR mutation patients have a favorable natural process, regardless of the efficacy of chemotherapy itself. Although a better outcome was found in mutation-positive NSCLC patients, this was not always obvious. Moreover, a majority of the previous related studies involved retrospective analysis and had a relatively small sample size, which could lead to some biases. Therefore, it is necessary to conduct further prospective studies to determine the predictive role of EGFR mutations for cytotoxic chemotherapy and the detailed prediction mechanism.
Comparison of the response to chemotherapy or EGFRTKIs between EGFR mutations in exon 19 and mutations in exon 21 in NSCLC
In different types of EGFR mutations, in-frame deletions in exon 19 and amino acid replacements in exon 21 (leucine to arginine at condon 858, p.L858R) were the most common mutations, and accounted for about 85% of all EGFR mutations in patients with NSCLC. [70] [71] [72] The predictive and prognostic value in patients with EGFR exon 19 mutation or with EGFR exon 21 mutation remains unclear (Table 3) . In research performed by Cappuzzo et al 73 
p.T790M mutation as a prognostic marker for patients with NSCLC
Some mechanisms of acquired resistance to EGFR-TKIs have been identified, such as MET amplification, small-cell histologic transformation, and HER2 amplification. [82] [83] [84] However, the p.T790M mutation is the most prevalent mechanism. p.T790M mutation was reported in 2.7%-40% of TKI-naïve patients. 20, 85 Currently, almost all patients with activating muta tions (deletion in exon 19 or point mutation in exon 21) eventually develop acquired resistance while receiving EGFR-TKI therapy, 20 and about 50% of these patients have a secondary mutation in exon 20 (p.T790M). [86] [87] [88] [89] [90] The p.T790M mutation abolishes the influence of EGFR-TKIs by increasing the affinity for adenosine triphosphate (ATP). 87 There is a major clinical problem in that NSCLC patients with EGFR mutations achieve acquired resistance after treatment with EGFR-TKIs.
Several studies have evaluated the predictive and prognostic role of p.T790M mutations in patients with NSCLC (Table 4) . The results of the study by Oxnard et al 91 showed that patients with p.T790M mutation at post-TKI biopsy had a longer post-progression survival compared with patients without p.T790M mutation after progression on EGFR-TKIs (19.0 versus 12.0 months, P=0.036). Moreover, those without p.T790M suffered a lower Karnofsky performance status at time of progression (P=0.007).
In the research of Fujita et al 92 38 EGFR-TKI-naïve patients with EGFR mutations who underwent curative pulmonary resection were included, and the EGFR p.T790M mutation at pre-TKI biopsy was detected in 30 patients (78.9%). There was no significant difference in TTF between those with and without p.T790M mutation (9.0 versus 7.0 months, P=0.44) after receiving EGFR-TKIs. However, the authors divided the patients with p.T790M mutation mutation into strongly positive and modestly positive groups according to the frequency of positive signals, and revealed that the patients who were strongly positive had a longer TTF compared with those without p.T790M mutation (P=0.0097) and those with modest positivity (P=0.0019). This was the first report to reveal a positive relationship between the Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; TTF, time to treatment failure; PFS, progression-free survival; PFS1, the time from the date of starting; PFS2, the time from the date of the first disease progression to the second disease progression; OS, overall survival; OS2, the time from the date of starting the therapy to death or last follow-up; NR, not reported.
Drug Design, Development and 23 ) between patients with and without p.T790M mutation. Thirty-four patients were treated with subsequent afatinib after progression on EGFR-TKIs, and the patients with p.T790M mutation had a higher RR than those without p.T790M mutation (5% versus 38%, P=0.01). However, the median PFS for afatinib was 3.2 months in the p.T790M mutation group and 4.6 months in the p.T790M wild-type group (P=0.33).
A meta-analysis 96 was performed to identify the role of EGFR p.T790M mutation in the prognosis of patients receiving EGFR-TKI therapy. The incidence of patients who had pretreatment p.T790M mutation ranged from 34.88% to 80.00%. The authors found that patients with p.T790M mutation had a shorter PFS on EGFR-TKI treatment compared with p.T790M wild-type patients.
The studies above evaluated whether there was a prognostic value to the p.T790M mutation in NSCLC patients with EGFR mutations, but this remains unclear. Rather than finding a negative prognostic effect of p.T790M mutation with EGFR-TKI treatment, some research has indicated that the p.T790M mutation might have a positive prognostic value after progression on EGFR-TKIs. In a fundamental study, the existence of p.T790M mutation was correlated with a slow speed of tumor growth, 86 which may be the reason why patients with EGFR p.T790M mutation were usually found to have a longer survival time in clinical research. Knowledge of p.T790M mutation is essential for determining the optimal treatment for these patients and we expect that the p.T790M mutation will become the first acquired molecular marker with prognostic significance.
Some studies have demonstrated that there were activities against p.T790M mutation tumors in vitro and in vivo, 97, 98 and some clinical trials are ongoing. 99, 100 The results of CO-1686 indicated that three-quarters of patients with p.T790M mutation who progressed following EGFR-TKIs treatment could have PR in a Phase I trial. 101 Preliminary data from a Phase I study in NSCLC patients with acquired resistance to EGFR-TKIs also showed that about one-half of the patients receiving AZD9291 treatment could achieve responses. 100, 102 Moreover, a Phase II trial suggested that the combination of cetuximab and afatinib had modest clinical activity in NSCLC patients with p.T790M mutation. 103 However, there is still no standard therapy for patients with p.T790M mutation.
First-line therapy in NSCLC patients with EGFR mutations
Six randomized Phase III trials indicated that NSCLC patients with EGFR mutations receiving EGFR-TKIs as the first-line therapy could achieve higher RR and longer PFS than those receiving chemotherapy; however, no significant difference was found in OS between the two groups (Table 5) . 51, 51, 78, 79, [105] [106] [107] [108] 110, 111 However, a pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials reported an improvement in OS in EGFR mutant patients receiving EGFR-TKIs in 2014. 77 Among the subgroup of NSCLC patients with EGFR mutation, the results of IPASS 51, 52 indicated that the gefitinib arm had a higher RR (71.2% versus 47.3%, P0.001) and a longer PFS (9.5 versus 6.3 months, P0.001) compared to the carboplatin/paclitaxel group, while no significant difference was found in OS between these two groups (21. Recently, in two randomized Phase III trials, 108,109 patients with EGFR mutations treated with second-generation EGFR-TKIs such as afatinib had better outcomes than those receiving chemotherapy (Table 5 ). The results of the LUXLung 3 study 108 demonstrated that significantly improved RR and PFS were found with afatinib compared to chemotherapy in EGFR mutation patients (56% versus 23%, P=0.001 and 11.1 versus 6.9 months, P=0.001, respectively). Similar results were found in the LUX-Lung 6 trial. 109 At the American Society of Clinical Oncology 2014 meeting, a pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials 77 provided new efficacy and safety data to support treatment with afatinib. The analysis included 631 advanced NSCLC patients with common EGFR mutations (deletions in exon 19 or p.L858R substitutions) and demonstrated that the patients attained longer OS when treated with first-line afatinib compared to standard chemotherapy (27.3 versus 24.3 months, HR 0.81, 95% CI: 0.66-0.99, P=0.037). This is the first time an actual survival benefit not seen in previous trials with gefitinib or erlotinib was shown.
The pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials 77 suggested that patients with EGFR mutations receiving EGFR-TKIs had a greater improvement in OS than those treated with chemotherapy, which provided the latest evidence toward determining whether EGFR-TKIs should be used as first-or second-line treatment. The results may influence the therapeutic regimen of the EGFR mutant patients in clinical practice. Afatinib is an irreversible inhibitor against p.T790M mutation and all EGFR family members. Although several related studies have been carried out, [110] [111] [112] [113] whether different EGFR-TKIs have different effects in EGFR-mutant patients is still unclear.
Conclusion
At present, EGFR mutation is the strongest predictive biomarker for the efficiency of EGFR-TKIs. 114, 115 Through analyzing relevant research of the past 20 years, we found that the prognostic and predictive value of EGFR mutation status in NSCLC remains uncertain, and it is difficult to understand the detailed mechanism by which cytotoxic agents influence EGFR-mutant and wild-type tumors differently. One study reported the differences in carcinogenic molecular genetic pathways between EGFR mutation tumors and tumors with wild-type EGFR. 116 The results showed that mutant EGFR selectively activated Akt and signal transducer and activator of transcription (STAT) signaling is related to cell survival; however, mutant EGFR could not act on extracellular signal-regulated kinase signaling, the function of which is to induce proliferation. Wildtype EGFR was proved to promote cellular proliferation and cell survival. Future molecular studies are needed to support this mechanism.
Although the majority of the selected research was performed retrospectively, and the studies achieved various conclusions, the results provide new information which can play an essential role in choosing the best treatment option for patients with NSCLC according to the EGFR mutation status. We believe that the presence of EGFR mutations has an intrinsic relationship with the outcomes in patients with NSCLC. With improvements in technology for detecting gene mutations, some novel mutations in EGFR have been reported to be sensitive to TKIs, such as p.V765A, p.T783A, p.V774A, p.S784P, and p.V769A. [117] [118] [119] [120] [121] The role of EGFR should be evaluated in more detail in prospectively designed research so that we can have a deeper understanding of the association of EGFR mutation with the curative effect and survival benefit of chemotherapy in the future.
Disclosure

